Physician profile
Vivek Agarwal
NPI 1467682799
$11,316.83
in general payments reported to CMS, 2019-2025
34 companies · $2,217 in 2025
The $2,217 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $1,188 · 2021: $1,304 · 2022: $2,146 · 2023: $2,107 · 2024: $2,125 · 2025: $2,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,306 · Education: $71.80 · Consulting Fee: $71.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,306.01 |
| Education | $71.80 |
| Consulting Fee | $71.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,809.88 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $1,163.38 | 2020-2025 | Cuvitru, Takhzyro, Glassia |
| Genzyme Corporation | $1,037.34 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,031.58 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Octapharma USA, INC. | $531.46 | 2020-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Biocryst US Sales Co., LLC | $405.05 | 2022-2025 | Orladeyo |
| Grifols USA, LLC | $396.55 | 2020-2025 | Xembify, Prolastin-C Liquid |
| Genentech USA, INC. | $389.03 | 2020-2025 | Xolair |
| Csl Behring | $386.92 | 2021-2025 | Hizentra, Andembry |
| Pfizer INC. | $380.68 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $335.23 | 2020-2024 | Spiriva Respimat |
| Kaleo, INC. | $306.49 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $293.47 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $254.07 | 2020-2025 | Dupixent |
| Amgen INC. | $205.49 | 2022-2025 | Tezspire |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $183.51 | 2020-2023 | Airduo Digihaler |
| Medtronic, INC. | $181.33 | 2024 | |
| Adma Biomanufacturing LLC | $153.51 | 2022-2025 | |
| Leo Pharma INC. | $126.23 | 2022-2023 | Adbry |
| Pharming Healthcare, INC. | $118.70 | 2022-2025 | Ruconest |
| Blueprint Medicines Corporation | $107.88 | 2023-2024 | Ayvakit |
| Alk-Abello, INC | $99.04 | 2022-2025 | Grastek, Odactra, Ragwitek |
| Horizon Therapeutics Plc | $69.11 | 2020-2022 | |
| Mylan Specialty L.P. | $66.38 | 2020-2024 | Yupelri |
| Ionis Pharmaceuticals, INC. | $41.02 | 2025 | Dawnzera |
| Aimmune Therapeutics, INC. | $39.54 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.38 | 2020-2021 | |
| Tersera Therapeutics LLC | $29.57 | 2024 | Quzyttir |
| Janssen Pharmaceuticals, INC | $29.42 | 2021 | |
| Sunovion Pharmaceuticals INC. | $23.65 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $22.77 | 2021 | |
| Abbvie INC. | $20.82 | 2023 | Rinvoq |
| Incyte Corporation | $19.89 | 2024 | Opzelura |
| Biocryst Pharmaceuticals, INC. | $18.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.